Total prevalent cases of painful diabetic neuropathy set to increase

The burden of painful diabetic neuropathy (PDN) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is expected to grow between 2016 and 2026. GlobalData epidemiologists forecast an increase in the number of total prevalent cases of PDN among the diabetic population, most notably in the US. Figure 1 presents the expected changes in the 7MM from 2016 to 2026.

admin January 23, 2018

Figure 1: 7MM, total prevalent cases of PDN, both sexes, ages ≥18 Years, 2016 and 2026. Credit: GlobalData.

PDN is a long-term complication of diabetes mellitus (DM). It is the result of decreased blood flow and high blood sugar levels, which develops over time into diabetic neuropathy, where patients experience neuropathic pain as a result of nerve damage.

There are different types of diabetic neuropathy, which can be grouped as peripheral, autonomic, proximal, and focal. Each type of neuropathy affects a different area of the body. Peripheral neuropathy, also known as distal symmetric neuropathy, diabetic polyneuropathy, or sensorimotor neuropathy, is the most common type of neuropathy, and affects toes, feet, legs, hands, and arms.

Among the 7MM, Japan has the greatest number of total prevalent cases of PDN for men and women ages 18 years and older, with 2,628,883 cases in 2016. The number of cases in Japan is expected to increase to 2,892,600 cases in 2026 at an Annual Growth Rate (AGR) of 1%.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The US is expected to see the greatest increase in the number of total prevalent cases of PDN, from 2,170,067 cases in 2016 to 3,391,934 cases in 2026 at an AGR of 5.63%. The 7MM will see an overall increase in the number of total prevalent cases of PDN from approximately one million cases in 2016 to 7.1 million cases in 2026 at an AGR of 4.94%.